Navigation Links
Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome
Date:2/1/2009

Westchester, Ill. A study in the Feb. 1 issue of the journal Sleep shows that the elevation in estradiol levels that occurs during pregnancy is more pronounced in pregnant women with restless legs syndrome (RLS) than in controls.

During the last trimester of pregnancy, levels of the estrogenic steroid hormone estradiol were 34,211 pg/mL in women with RLS and 25,475 pg/mL in healthy controls. At three months postpartum, estradiol levels had dropped to 30.73 pg/mL in the RLS group and 94.92 pg/mL in controls. Other hormone levels did not differ significantly between the study groups.

According to the authors the data strongly suggest that estrogens play an important role in RLS during pregnancy. The study also supports previous reports of high RLS incidence in the last trimester of pregnancy when estradiol is maximally elevated.

"Our findings strongly support the concept that neuroactive hormones play a relevant pathophysiological role in RLS," said principal investigator Thomas Pollmacher, MD, director of the Center for Medical Health at Klinikum Ingolstadt and professor of psychiatry at Ludwig Maximilians University in Munich, Germany. "This information will increase the understanding of RLS in pregnancy and will assist in the development of specific therapeutic approaches."

The American Academy of Sleep Medicine describes RLS as a sleep-related movement disorder that involves an almost irresistible urge to move the legs at night. This urge tends to be accompanied by unusual feelings or sensations, called "paresthesias," that occur deep in the legs. These uncomfortable sensations often are described as a burning, tingling, prickling or jittery feeling. RLS can profoundly disturb a person's ability to go to sleep or return to sleep after an awakening.

The AASM reports that RLS occurs 1.5 to two times more often in women than in men. Eighty percent to 90 percent of people with RLS also experience periodic limb movements (PLMs) during sleep, which are involuntary jerking or twitching movements of the feet or legs.

According to the authors RLS symptoms often occur for the first time during pregnancy. Symptoms typically worsen during pregnancy and improve or even disappear after delivery. The risk of developing RLS increases gradually with the number of pregnancies.

The study also found that women with RLS had more PLMs than controls before and after delivery. PLMs decreased significantly after delivery in women with RLS and stayed low in women without RLS.

Only minor differences appeared between the two study groups in subjective sleep quality and objective sleep measures. One explanation suggested by the authors is that only RLS patients who did not need pharmacological treatment were selected for the study; RLS symptoms of participants were in the mild to moderate range.

The study involved nine healthy pregnant women (mean age 32.9 years) who were placed in a control group and 10 pregnant women (mean age 31.6 years) who fulfilled diagnostic criteria for RLS. Eight women from the RLS group reported symptoms previous to the present pregnancy, and all members of the RLS group described worsening of symptoms during pregnancy. The mean age of onset for RLS symptoms was 22.6 years.

Sleep data and leg movements were recorded during overnight polysomnography around the 36th week of gestation and again at 12 weeks postpartum. Blood samples were taken each morning after the polysomnography and before breakfast. Accompanying questionnaires on sleep and RLS symptoms also were collected.


'/>"/>

Contact: Kelly Wagner
kwagner@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. 15% of Women Struggle With Pregnancy-Related Depression
2. Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery
3. Hormonal Changes and Depression: What is the Connection?
4. Hormonal dietary supplements might promote prostate cancer progression
5. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
6. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
7. Inheritance of hormonal disorder marked by excessive insulin in daughters
8. Non-Hormonal Therapies Aid Breast Cancer Patients
9. Arbios Announces Management Changes
10. Renovis Announces Management Changes
11. Bradmer announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Conference from Sept. 18 to 20. , The two-day conference is focused on ... the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. The ...
(Date:6/23/2017)... ... , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves clients ... (FEMA) recent update of flood zones, more people than ever are in flood ... to reflect the actual risk in flood zone areas during a time when ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, ... communities in the greater Chicago metropolitan area, is embarking on a charity drive ... in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the ...
(Date:6/22/2017)... FL (PRWEB) , ... June 22, 2017 , ... Branches, ... received more than $245,000 in grant funding to support its programs focused on providing ... Branches, Inc. was awarded a grant by the Foundation of $15,000 to support its ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health System ... (AHA) to launch a Rheumatic Heart Disease Center, with the goal of developing ... heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of ... test failure code.     ... PART NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
Breaking Medicine Technology: